Table 4 Unadjusted and adjusted hazard ratios for the factors associated with PFS to cisplatin/gemcitabine among patients with MPM
HR (95% CI) | p-Value | HR (95% CI) | p-value | |
|---|---|---|---|---|
Sex | 1.83 (0.85–3.97) | 0.124 | 1.36 (0.46–4.01) | 0.573 |
Age, 60+ years | 1.27 (0.58–2.76) | 0.552 | ||
Tobacco exposure | 1.08 (0.49–2.37) | 0.843 | ||
Exposure to asbestos | 0.61 (0.28–1.33) | 0.218 | ||
ECOG PS | 2.01 (0.92–4.39) | 0.080 | ||
Histology | 2.90 (1.20–7.02) | 0.018 | ||
Karnofsky | 0.61 (0.28–1.33) | 0.215 | ||
Disease stage | 0.74 (0.34–1.63) | 0.457 | ||
ERCC1 | 0.95 (0.39–2.31) | 0.915 | ||
RRM1 | 0.11 (0.02–0.52) | 0.005 | 0.11 (0.02–0.52) | 0.005 |
RRM2 | 0.71 (0.24–2.09) | 0.532 | ||
hENT-1 | 1.13 (0.47–2.74) | 0.780 |